10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Ben Hindson

Serge Saxonov

10x Genomics, Inc.

Iambic Therapeutics develops AI-driven platforms for drug discovery, focusing on optimizing medicines for specific disease profiles and addressing unmet patient needs. The company self-describes its approach as innovative and efficient.

Iambic Therapeutics

Genotypic Technology Pvt. Ltd. is a genomics solution provider offering Next Generation Sequencing (NGS), Microarray, and Bioinformatics services, solutions, and products. It serves domestic and international pharmaceutical, biotech companies, and academia.

Genotypic Technology Pvt. Ltd.

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

10x Genomics

 #Singlecellspatial lets researchers like Dr. Nick Banovich take their research to the next level by offering gross tissue morphology and single-molecule RNA transcript detection at subcellular resolution on a single section. Hear why he was excited to get his hands on Xenium #InSitu in a quick clip below, then watch the full webinar for more! https://lnkd.in/gurVFX-r

We just wrapped up an amazing, empowering week in Palm Springs with our global commercial team! 🌴🎉 The week unfolded with a focus on innovation and professional development featuring keynote speakers and breakout sessions. Did we mention we also had a ton of fun?! We had an array of team-building activities, from early morning sessions of pickleball and yoga, to carnival booth games, to an "Old Hollywood''-themed awards celebration and dinner. A HUGE thanks to our amazing commercial team who brought collaborative energy, shared powerful insights, and strengthened professional relationships. 🙌 

Hippos eat more than 80 lbs of food a day to support their massive size. Organs use the Hippo pathway—which controls organ size by regulating cell proliferation and apoptosis. #Cancer often takes advantage of the Hippo pathway to boost tumor growth, but therapeutically targeting it is challenging. Check out this study to see how Genentech researchers used #singlecell methods to measure the efficacy of their small molecule inhibitor candidate! 

Heart defects are the leading cause of fetal death, but, historically, research on this important subject has been difficult for a number of reasons, including the inaccessibility of human embryonic samples and the limitations of in vitro models. However, in honor of #AmericanHeartMonth, we’re highlighting a recent paper that uncovered new insights into underlying defects in the developing human heart, using our #singlecell Flex assay to generate compartment-specific, in vivo–like gene expression profiles. Read the paper!

What do mini-kidneys, tiny tumors, and little livers have in common? They were highlighted in one of our top blogs from 2023! Read the blog to learn how scientists are using #organoid models and high-resolution #singlecell analysis to identify druggable disease pathways, screen drugs, model drug metabolism, and explore patient-specific therapeutic responses! 

Metric
Company Name	10	Iambic Therapeutics	Genotypic Technology Pvt. Ltd.
Symbol	TXG
MSH ID	COM:10XGENOMICS	AI:IAMBIC	IN:CO:GENOTYPIC
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Healthcare Information Services	Biotechnology	Biotechnology
Country	US	US	IN
Stage	Post-IPO
Employee Count	1.26K	59
Website	10xgenomics.com	iambic.ai	genotypic.co.in
LinkedIn	10xgenomics
Founders

Metric
Market Cap	1.88B
Enterprise Value
Monthly Web Traffic	150.48K	3.40K
Web Traffic Growth	-0.39	1.28
Valuation
Raised Capital		1M

Metric
Revenue	618.73M
Revenue (LTM)
Revenue (NTM)
Gross Profit	409.31M
EBITDA	-158.25M
Operating Income	-201.87M
Net Income	-255.10M
EPS	-2.18
Diluted EPS	-2.18
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65
Operating Profit Margin	-0.37
EBITDA Margin	-0.26
Net Profit Margin	-0.38
Return on Equity	-0.33
Return on Assets	-0.26
Return on Capital Employed	-0.28

COM:10XGENOMICS

10x Genomics, Inc.

Last Close

13.29

22/11 21:00

Market Cap

1.88B

Beta: -

Volume Today

5.63M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-22.67
P/B Ratio	6.79
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.04
EV Multiple	-9.56

Metric
Days Sales Outstanding	64.14
Days Payables Outstanding	38.61
Days Inventory Outstanding	141.51
Operating Cycle	194.20
Cash Conversion Cycle	164.30
Asset Turnover	0.68

Metric
Operating Cash Flow	-15.20M
Free Cash Flow	-64.72M
Cash Flow to Debt	-0.09
Operating Cash Flow/Sales	-0.01
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	359.28M
Accounts Receivable	-10.61M
Inventory	73.71M
Goodwill	4.51M
Debt to Capitalization	0.11
Debt to Assets	0.10
Current Ratio	5.37
Quick Ratio	4.45

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.29
R&D to Revenue	0.52
SG&A to Revenue